Nutriband Inc
NTRB4.350USD
+0.005+0.12%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
52.88M시가총액
손실P/E TTM
자세한 내용은 Nutriband Inc 회사
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Nutriband Inc 정보
종목 코드 NTRB
회사 이름Nutriband Inc
상장일Jun 20, 2017
CEOMelnik (Serguei)
직원 수- -
유형Ordinary Share
회계 연도 종료Jun 20
주소121 S Orange Ave Ste 1500
도시ORLANDO
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호32801-3241
전화14073776695
웹사이트https://nutriband.com/
종목 코드 NTRB
상장일Jun 20, 2017
CEOMelnik (Serguei)
Nutriband Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
939.42K
+119000.00%
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
13.96K
-3249.00%
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
1.17K
--
Dr. Alan Smith, Ph.D.
Dr. Alan Smith, Ph.D.
Chief Operating Officer, President of 4P Therapeutics
Chief Operating Officer, President of 4P Therapeutics
--
--
Prof. Dr. Stefani C. Mancas
Prof. Dr. Stefani C. Mancas
Independent Director
Independent Director
--
--
Mr. Sergei Glinka
Mr. Sergei Glinka
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Serguei Melnik
Mr. Serguei Melnik
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
Chairman of the Board, President, Interim Chief Executive Officer, Secretary
939.42K
+119000.00%
Mr. Gerald Goodman
Mr. Gerald Goodman
Chief Financial Officer
Chief Financial Officer
86.33K
--
Dr. Jeff Patrick, Pharm.D.
Dr. Jeff Patrick, Pharm.D.
Chief Scientific Officer
Chief Scientific Officer
36.61K
--
Mr. Radu Bujoreanu
Mr. Radu Bujoreanu
Independent Director
Independent Director
15.75K
--
Mr. Mark Hamilton
Mr. Mark Hamilton
Independent Director
Independent Director
13.96K
-3249.00%
Ms. Irina Gram
Ms. Irina Gram
Independent Director
Independent Director
1.17K
--
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2026Q3
FY2026Q2
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Sale of goods
346.06K
0.00%
Services
0.00
0.00%
지역별USD
이름
수익
비율
United States
346.06K
100.00%
Non-United States
0.00
0.00%
사업별
지역별
사업별USD
이름
수익
비율
Sale of goods
346.06K
0.00%
Services
0.00
0.00%
주식 보유 통계
마지막 업데이트: Sat, Jan 31
마지막 업데이트: Sat, Jan 31
주주
주주 유형
주주
주주
비율
Botgros (Vitalie)
26.44%
TII Jet Services, LDA
14.85%
Sheridan (Gareth)
14.47%
Glinka (Serguei)
9.19%
Melnik (Serguei)
7.72%
기타
27.33%
주주
주주
비율
Botgros (Vitalie)
26.44%
TII Jet Services, LDA
14.85%
Sheridan (Gareth)
14.47%
Glinka (Serguei)
9.19%
Melnik (Serguei)
7.72%
기타
27.33%
주주 유형
주주
비율
Individual Investor
59.53%
Corporation
14.85%
Investment Advisor
2.06%
Investment Advisor/Hedge Fund
0.82%
Research Firm
0.04%
기타
22.70%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
40
355.48K
2.92%
-101.91K
2025Q3
36
350.65K
2.91%
-71.29K
2025Q2
44
8.87M
79.52%
+489.89K
2025Q1
43
8.13M
73.14%
+1.78M
2024Q4
40
8.04M
72.39%
+1.68M
2024Q3
40
8.08M
72.79%
+1.82M
2024Q2
38
5.19M
52.25%
+2.18M
2024Q1
34
4.36M
55.65%
+1.38M
2023Q4
30
4.30M
54.90%
+1.31M
2023Q3
29
2.96M
37.78%
-39.44K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Botgros (Vitalie)
3.22M
26.44%
+132.25K
+4.28%
Dec 17, 2025
TII Jet Services, LDA
1.81M
14.85%
+485.05K
+36.66%
Sep 01, 2024
Sheridan (Gareth)
1.76M
14.47%
--
--
Dec 17, 2025
Glinka (Serguei)
1.12M
9.19%
+294.04K
+35.64%
Dec 17, 2025
Melnik (Serguei)
939.42K
7.72%
+119.00K
+14.50%
Dec 17, 2025
The Vanguard Group, Inc.
202.74K
1.67%
+3.11K
+1.56%
Sep 30, 2025
Goodman (Gerald)
86.33K
0.71%
--
--
Dec 17, 2025
Geode Capital Management, L.L.C.
59.94K
0.49%
-3.69K
-5.80%
Sep 30, 2025
Smith (Allan)
36.91K
0.3%
-5.00K
-11.93%
Dec 17, 2025
Patrick (Jeff)
36.61K
0.3%
--
--
Dec 17, 2025
더 보기
관련 ETF
마지막 업데이트: Tue, Dec 2
마지막 업데이트: Tue, Dec 2
이름
비율
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Jul 29, 2022
Split
6→7
날짜
배당락일
유형
비율
Jul 29, 2022
Split
6→7
